Review of latent and lytic phase biomarkers in Kaposi's sarcoma

Bibliography

• Kaposi M. Idiopathisces multiples Pigmentsarkom der Haut. Archiv fur Dermatologi und Syphilis 1872;3:265-73
   Google Scholar
• Wen KW, Damania B. Kaposi sarcoma-associated herpesvirus (KSHV): molecular biology and oncogenesis. Cancer Lett 2010;289(2):140-50
   PubMed Web of Science ®Google Scholar
• Lodi S, Guiguet M, Costagliola D, et al. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst 2010;102(11):784-92
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Roque-Afonso AM, Hurtova M, et al. Fatal disseminated Kaposi's sarcoma following human herpesvirus 8 primary infections in liver-transplant recipients. Liver Transpl 2004;10(2):295-300
   PubMed Web of Science ®Google Scholar
• Nguyen HQ, Magaret AS, Kitahata MM, et al. Persistent Kaposi sarcoma in the era of HAART: characterizing the predictors of clinical response. AIDS 2008;22(8):937-45
   PubMed Web of Science ®Google Scholar
• Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection. N Engl J Med 1995;332(18):1181-5
   PubMed Web of Science ®Google Scholar
• Douglas JL, Gustin JK, Dezube B, et al. Kaposi's sarcoma: a model of both malignancy and chronic inflammation. Panminerva Med 2007;49(3):119-38
   PubMed Web of Science ®Google Scholar
• Lim C, Sohn H, Lee D, et al. Functional dissection of latency-associated nuclear antigen 1 of Kaposi's sarcoma-associated herpesvirus involved in latent DNA replication and transcription of terminal repeats of the viral genome. J Virol 2002;76(20):10320-31
   PubMed Web of Science ®Google Scholar
• Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med 2013;137(2):289-94
   PubMed Web of Science ®Google Scholar
• Wang T, Pantanowitz L. Recent advances in Kaposi sarcoma. J Oncopath 2013;1(1):55-66
   Google Scholar
• Pantanowitz L, Caponetti G, Dezube BJ. The immunohistochemistry of Kaposi's sarcoma. Methods of Cancer Diagnosis. Ther Prognosis 2010;6:405-31
   Google Scholar
• Robin Y, Guillou L, MichelsCoindre J. Human herpesvirus 8 immunostaining: a sensitive and specific method for diagnosing Kaposi sarcoma in paraffin-embedded sections. Am J Clin Pathol 2004;121:330-4
   PubMed Web of Science ®Google Scholar
• Pantanowitz L, Pinkus GS, Dezube BJ, Tahan SR. HHV8 is not limited to Kaposi's sarcoma. Mod Pathol 2005;18:1148
   PubMed Web of Science ®Google Scholar
• Cheuk W, Wong KOY, Wong CSC, et al. Immunostaining for human herpesvirus 8 latent nuclear antigen-1 helps distinguish Kaposi sarcoma from its mimickers. Am J Clin Pathol 2004;121:335-42
   PubMed Web of Science ®Google Scholar
• Ramos-da-Silva S, Elgui-de-Oliveira D, Borges L, Bacchi CE. Kaposi's sarcoma-associated herpesvirus infection and Kaposi's sarcoma in Brazil. Braz J Med Biol Res 2006;39(5):573-80
   PubMed Web of Science ®Google Scholar
• Moore PS. Human herpesvirus 8 variants [letter]. Lancet 1998;351:679
   PubMed Web of Science ®Google Scholar
• Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999;96:4546-51
   PubMed Web of Science ®Google Scholar
• Schwartz EJ, Dorfman RF, Kohler S. Human herpesvirus-8 latent nuclear antigen-1 expression in endemic Kaposi sarcoma: an immunohistochemical study of 16 cases. Am J Surg Pathol 2003;27:1546-50
   PubMed Web of Science ®Google Scholar
• Verma SC, Lan K, Robertson E. Structure and function of latency-associated nuclear antigen. Curr Top Microbiol Immunol 2007;312:101-36
   PubMed Web of Science ®Google Scholar
• Radkov SA, Kellam P, Boshoff C. The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells. Nat Med 2000;6:1121-7
   PubMed Web of Science ®Google Scholar
• Pyakurel P, Pak F, Mwakigonja AR, et al. Lymphatic and vascular origin of Kaposi's sarcoma spindle cells during tumor development. Int J Cancer 2006;119:1262-7
   PubMed Web of Science ®Google Scholar
• Pyakurel P, Pak F, Mwakigonja AR, et al. KSHV/HHV-8 and HIV infection in Kaposi's sarcoma development. Infect Agent Cancer 2007;2:4
   PubMedGoogle Scholar
• Chen W, Hilton IB, Staudt MR, et al. Distinct p53, p53:LANA, and LANA complexes in Kaposi's sarcoma-associated herpesvirus lymphomas. J Virol 2010;84(8):3898-908
   PubMed Web of Science ®Google Scholar
• Knight JS, Cotter MA, Robertson ES. The latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirustransactivates the telomerase reverse transcriptase promoter. J Biol Chem 2001;276:22971-8
   PubMed Web of Science ®Google Scholar
• Verma SC, Borah S, Robertson ES. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus up-regulates transcription of human telomerase reverse transcriptase promoter through interaction with transcription factor Sp1. J Virol 2004;78:10348-59
   PubMed Web of Science ®Google Scholar
• Flore O, Rafii S, Ely S, et al. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus. Nature 1998;394:588-92
   PubMed Web of Science ®Google Scholar
• Kwun HJ, da Silva SR, Shah IM, et al. Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics epstein-barr virus EBNA1 immune evasion through central repeat domain effects on protein processing. J Virol 2007;81(15):8225-35
   PubMed Web of Science ®Google Scholar
• van Bogaert LJ. Immunostaining by human herpes virus 8 latent nuclear antigen-1 of Kaposi's sarcoma: a potential biomarker of severity of disease? J Mol Biomark Diagn 2013;S5:002- doi:10.4172/2155-9929.S5-002
   Google Scholar
• Moore PS, Chang Y. Kaposi's sarcoma-associated herpesvirusimmunoevasion and tumorigenesis: two sides of the same coin? Annu Rev Microbiol 2003;57:609-39
   PubMed Web of Science ®Google Scholar
• Thome M, Schneider P, Hofmann K, et al. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature 1997;386(6624):517-21
   PubMed Web of Science ®Google Scholar
• Alkharsah KR, Singh VV, Bosco R, et al. Deletion of Kaposi's sarcoma-associated herpesvirus FLICE inhibitory protein, vFLIP, from the viral genome compromises the activation of STAT1-responsive cellular genes and spindle cell formation in endothelial cells. J Virol 2011;85(19):10375-88
   PubMed Web of Science ®Google Scholar
• Chugh P, Matta H, Schamus S, et al. Constitutive NF-κB activation, normal Fas-induced apoptosis, and increased incidence of lymphoma in human herpes virus 8 K13 transgenic mice. PNAS 2005;102(36):12885-90
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Jasmin A, Eby MT, Hood L. Modulation of the NF-κB pathway by virally encoded death effector domains-containing proteins. Oncogene 1999;18:5738-46
   PubMed Web of Science ®Google Scholar
• Sakakibara S, Espigol-Frigole G, Gasperini P, et al. A20/TNFAIP3 inhibits NF-κB activation induced by the Kaposi's sarcoma-associated herpesvirus vFLIP oncoprotein. Oncogene 2013;32(10):1223-32
   PubMed Web of Science ®Google Scholar
• Keller SA, Schattner EJ, Cesarman E. Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 2000;96(7):2537-42
   PubMed Web of Science ®Google Scholar
• Guasparri I, Keller SA, Cesarman E. KSHV vFLIP is essential for the survival of infected lymphoma cells. J Exp Med 2004;199(7):993-1003
   PubMed Web of Science ®Google Scholar
• Field N, Low W, Daniels M, et al. KSHV vFLIP binds to IKK-γ to activate IKK. Journal of Cell Science. 2003;116:3721-8
   Google Scholar
• Guasparri I, Wu H, Cesarman E. The KSHV oncoprotein vFLIP contains a TRAF-interacting motif and requires TRAF2 and TRAF3 for signaling. EMBO Rep 2006;7(1):114-19
   PubMed Web of Science ®Google Scholar
• Matta H, Gopalakrishnan R, Graham C, et al. Kaposi's sarcoma associated herpesvirus encoded viral FLICE inhibitory protein K13 activates NF-κB pathway independent of TRAF6, TAK1 and LUBAC. PLoS One 2012;7(5):e36601
   PubMedGoogle Scholar
• Masuda Y, Noguchi K, Segawa H, et al. Novel regulatory role for Kaposi's sarcoma-associated herpesvirus-encoded vFLIP in chemosensitization to bleomycin. Biochem Biophys Res Commun 2011;415(2):305-12
   PubMed Web of Science ®Google Scholar
• Davis MA, Stürzl MA, Blasig C, et al. Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells. J Natl Cancer Inst 1997;89:1868-74
   PubMed Web of Science ®Google Scholar
• Reed JA, Nador RG, Spaulding D, et al. Demonstration of Kaposi's sarcoma-associated herpesviruscyclin D homolog in cutaneous Kaposi's sarcoma by colorimetric in situ hybridization using a catalyzed signal amplification system. Blood 1998;91(10):3825-32
   PubMed Web of Science ®Google Scholar
• Li M, Lee H, Yoon DW, et al. Kaposi's sarcoma-associated herpesvirus encodes a functional cyclin. J Virol 1997;71:1984-91
   PubMed Web of Science ®Google Scholar
• Ellis M, Chew YP, Fallis L, et al. Degradation of p27(Kip) cdk inhibitor triggered by Kaposi's sarcoma virus cyclin-cdk6 complex. EMBO J 1999;18(3):644-53
   PubMed Web of Science ®Google Scholar
• Godden-Kent D, Talbot SJ, Boshoff C, et al. The cyclin encoded by Kaposi's sarcoma-associated herpesvirus stimulates cdk6 to phosphorylate the retinoblastoma protein and histone H1. J Virol 1997;71:4193-8
   PubMed Web of Science ®Google Scholar
• Mann DJ, Child ES, Swanton C, et al. Modulation of p27Kip1 levels by the cyclin encoded by Kaposi's sarcoma-associated herpesvirus. EMBO J 1999;18:654-63
   PubMed Web of Science ®Google Scholar
• Laman H, Coverley D, Krude T, et al. Viral cyclin-cyclin-dependent kinase 6 complexes initiate nuclear DNA replication. Mol Cell Biol 2001;21:624-35
   PubMedGoogle Scholar
• Swanton C, Mann DJ, Fleckenstein B, et al. Herpes viral cyclin/cdk6 complexes evade inhibition by cdk inhibitor proteins. Nature 1997;390:184-7
   PubMed Web of Science ®Google Scholar
• Verschuren EW, Hodgson JG, Gray JW, et al. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res 2004;64(2):581-9
   PubMed Web of Science ®Google Scholar
• Shin YC, Nakamura H, Liang X, et al. Inhibition of the ATM/p53 signal transduction pathway by Kaposi's sarcoma-associated herpesvirus interferon regulatory factor 1. J Virol 2006;80(5):2257-66
   PubMed Web of Science ®Google Scholar
• Zhong W, Wang H, Herndier B, Ganem D. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci USA 1996;93:6641-6
   PubMed Web of Science ®Google Scholar
• Staskus KA, Zhong W, Gebhard K, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol 1997;71(1):715-19
   PubMed Web of Science ®Google Scholar
• Muralidhar S, Pumfery AM, Hassani M, et al. Identification of kaposin (ORF K12) as a human herpesvirus 8 (Kaposi's sarcoma associated herpesvirus) transforming gene. J Virol 1998;72:4980-8
   PubMed Web of Science ®Google Scholar
• Kliche S, Nagel W, Kremmer E, et al. Signaling by human herpesvirus 8 kaposin A through direct membrane recruitment of cytohesin-1. Mol Cell 2001;7(4):833-43
   PubMed Web of Science ®Google Scholar
• Sadler R, Wu L, Forghani B, et al. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol 1999;73(7):5722-30
   PubMed Web of Science ®Google Scholar
• McCormick C, Ganem D. Phosphorylation and function of the Kaposin B direct repeats of Kaposi's sarcoma-associated herpesvirus. J Virol 2006;80(12):6165-70
   PubMed Web of Science ®Google Scholar
• King CA. KSHV Kaposin B induces unique mono-phosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor, TRIM28. J Virol 2013; Epub ahead of print
   Web of Science ®Google Scholar
• Yoo J, Kang J, Lee HN, et al. Kaposin-B enhances the PROX1 mRNA stability during lymphatic reprogramming of vascular endothelial cells by Kaposi's sarcoma herpes virus. PLoS Pathog 2010;6(8):e1001046
   PubMedGoogle Scholar
• Bais C, Santomasso B, Coso O, et al. G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature 1998;391:86-9
   PubMed Web of Science ®Google Scholar
• Qin D, Feng N, Fan W, et al. Activation of PI3K/AKT and ERK MAPK signal pathways is required for the induction of lytic cycle replication of Kaposi's sarcoma-associated herpesvirus by herpes simplex virus type 1. BMC Microbiol 2011;11:240
   PubMedGoogle Scholar
• Martin D, Galisteo R, Molinolo AA, et al. PI3Kγ mediates kaposi's sarcoma-associated herpesvirus vGPCR-induced sarcomagenesis. Cancer Cell 2011;19(6):805-13
   PubMed Web of Science ®Google Scholar
• Montaner S, Sodhi A, Molinolo A, et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003;3:23-36
   PubMed Web of Science ®Google Scholar
• Jham BC, Montaner S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor: lessons on dysregulated angiogenesis from a viral oncogene. J Cell Biochem 2010;110:1-9
   PubMed Web of Science ®Google Scholar
• Martin D, Galisteo R, Ji Y, et al. An NF-κB gene expression signature contributes to Kaposi's sarcoma virus vGPCR-induced direct and paracrine neoplasia. Oncogene 2008;27:1844-52
   PubMed Web of Science ®Google Scholar
• Bais C, Van Geelen A, Eroles P, et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 2003;3:131-43
   PubMed Web of Science ®Google Scholar
• Cannon M, Philpott NJ, Cesarman E. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. J Virol 2003;77:57-67
   PubMed Web of Science ®Google Scholar
• Yang TY, Chen SC, Leach MW, et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi's sarcoma. J Exp Med 2000;191:445-54
   PubMed Web of Science ®Google Scholar
• Sodhi A, Montaner S, Patel V, et al. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc Natl Acad Sci USA 2004;101(14):4821-6
   PubMed Web of Science ®Google Scholar
• Glaunsinger B, Ganem D. Highly selective escape from KSHV-mediated host mRNA shutoff and its implications for viral pathogenesis. J Exp Med 2004;200(3):391-8
   PubMed Web of Science ®Google Scholar
• Montaner S, Sodhi A, Ramsdell AK, et al. The KSHV GPCR as a therapeutic target for the treatment of Kaposi's sarcoma. Cancer Res 2006;66:168-74
   PubMed Web of Science ®Google Scholar
• Lee BS, Connole M, Tang Z, et al. Structural analysis of the Kaposi's sarcoma-associated herpesvirus K1 protein. J Virol 2003;77(14):8072-86
   PubMed Web of Science ®Google Scholar
• Lee H, Veazey R, Williams K, et al. Deregulation of cell growth by the K1 gene of Kaposi's sarcoma-associated herpesvirus. Nat Med 1998;4:435-40
   PubMed Web of Science ®Google Scholar
• Lagunoff M, Majeti R, Weiss A, Ganem D. Deregulated signal transduction by the K1 gene product of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA 1999;96(10):5704-9
   PubMed Web of Science ®Google Scholar
• Damania B. Modulation of cell signaling pathways by Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8). Cell Biochem Biophys 2004;40(3):305-22
   PubMed Web of Science ®Google Scholar
• Lanier LL. Viral immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling in cell transformation and cancer. Trends Cell Biol 2006;16(8):388-90
   PubMed Web of Science ®Google Scholar
• Prakash O, Swamy OR, Peng X, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 2005;105(10):3987-94
   PubMed Web of Science ®Google Scholar
• Wang S, Wang S, Maeng H, et al. K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis. Blood 2007;109(5):2174-82
   PubMed Web of Science ®Google Scholar
• Lagunoff M, Lukac DM, Ganem D. Immunoreceptor tyrosine-based activation motif-dependent signaling by Kaposi's sarcoma-associated herpesvirus K1 protein: effects on lytic viral replication. J Virol 2001;75(13):5891-8
   PubMed Web of Science ®Google Scholar
• Wang HW, Trotter MW, Lagos D, et al. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet 2004;36(7):687-93
   PubMed Web of Science ®Google Scholar
• Wen KW, Damania B. Hsp90 and Hsp40/Erdj3 are required for the expression and anti-apoptotic function of KSHV K1. Oncogene 2010;29(24):3532-44
   PubMed Web of Science ®Google Scholar
• Aresté C, Mutocheluh M, Blackbourn DJ. Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirusimmunoregulatory protein. J Biol Chem 2009;284(35):23272-85
   PubMed Web of Science ®Google Scholar
• Jacobs SR, Damania B. The viral interferon regulatory factors of KSHV: immunosuppressors or oncogenes? Front Immunol 2011;2(19):1-11
   Google Scholar
• Xi X, Persson LM, O'Brien MW, et al. Cooperation between viral interferon regulatory factor 4 and RTA to activate a subset of Kaposi's sarcoma-associated herpesvirus lytic promoters. J Virol 2012;86(2):1021-33
   PubMed Web of Science ®Google Scholar
• Gao S, Bosho C, Jayachandra S, et al. KSHV ORF K9 (vIRF) is an oncogene which inhibits the interferon signaling pathway. Oncogene 1997;15:1979-85
   PubMed Web of Science ®Google Scholar
• Li M, Lee H, Guo J, et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor. J Virol 1998;72:5433-40
   PubMed Web of Science ®Google Scholar
• Seo T, Park J, Lee D, et al. Viral interferon regulatory factor 1 of Kaposi's sarcoma-associated herpesvirus binds to p53 and represses p53-dependent transcription and apoptosis. J Virol 2001;75(13):6193-8
   PubMed Web of Science ®Google Scholar
• Jayachandra S, Low K, Thlick AE, et al. Three unrelated viral transforming proteins (vIRF, EBNA2 and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. Proc Natl Acad Sci USA 1999;96:11566-71
   PubMed Web of Science ®Google Scholar
• Burysek L, Yeow W, Lubyova B, et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol 1999;73:7334-42
   PubMed Web of Science ®Google Scholar
• Li M, Damania B, Alvarez X, et al. Inhibition of p300 histone acetyltransferase by viral interferon regulatory factor. Mol Cell Biol 2000;20(21):8254-63
   PubMed Web of Science ®Google Scholar
• Nakamura H, Li M, Zarycki J, et al. Inhibition of p53 tumor suppressor by viral interferon regulatory factor. J Virol 2001;75(16):7572-82
   PubMed Web of Science ®Google Scholar
• Seo T, Park J, Choe J. Kaposi's sarcoma-associated herpesvirus viral IFN regulatory factor 1 inhibits transforming growth factor-beta signaling. Cancer Res 2005;65(5):1738-47
   PubMed Web of Science ®Google Scholar
• Lee HR, Toth Z, Shin YC, et al. Kaposi's sarcoma-associated herpesvirus viral interferon regulatory factor 4 targets MDM2 to deregulate the p53 tumor suppressor pathway. J Virol 2009;83(13):6739-47
   PubMed Web of Science ®Google Scholar
• Sullivan R, Pantanowitz L, Dezube BJ. Chemokine and signal transduction targets in Kaposi sarcoma. In: Pantanowitz L, Stebbing J, Dezube BJ, editors, Kaposi sarcoma. A model of oncogenesis. Research Signpost; Kerala, India; 2010. p. 83-99
   Google Scholar
• Gottwein E. Kaposi's sarcoma-associated herpesvirus microRNAs. Front Microbiol 2012;3:165
   Google Scholar
• Ramalingam D, Kieffer-Kwon P, Ziegelbauer JM. Emerging themes from EBV and KSHV microRNA targets. Viruses 2012;4:1687-710
   PubMed Web of Science ®Google Scholar
• Chugh PE, Sin SH, Ozgur S, et al. Systemically circulating viral and tumor-derived microRNAs in KSHV-associated malignancies. PLoS Pathog 2013;9(7):e1003484
   PubMed Web of Science ®Google Scholar
• O'Hara AJ, Chugh P, Wang L, et al. Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog 2009;5(4):e1000389
   PubMedGoogle Scholar
• Nascimento MC, de Souza VA, Sumita LM, et al. Comparative study of Kaposi's sarcoma-associated herpesvirus serological assays using clinically and serologically defined reference standards and latent class analysis. J Clin Microbiol 2007;45(3):715-20
   PubMed Web of Science ®Google Scholar
• Laney AS, Peters JS, Manzi SM, et al. Use of a multiantigen detection algorithm for diagnosis of Kaposi's sarcoma-associated herpesvirus infection. J Clin Microbiol 2006;44(10):3734-41
   PubMed Web of Science ®Google Scholar
• Mbisa GL, Miley W, Gamache CJ, et al. Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J Immunol Methods 2010;356(1-2):39-46
   PubMed Web of Science ®Google Scholar
• Ouyang XX, Fu BS, Li BL, et al. Establishment of an ELISA to detect Kaposi's sarcoma-associated herpesvirus using recombinant ORF73. Virol Sin 2010;25(3):168-76
   PubMedGoogle Scholar
• Gogineni E, Marshall V, Miley W, et al. Quantitative determinations of anti-Kaposi sarcoma-associated herpesvirus antibody levels in men who have sex with men. Diagn Microbiol Infect Dis 2013;76(1):56-60
   PubMed Web of Science ®Google Scholar
• Pantanowitz L. Kaposi sarcoma: appraisal of therapeutic agents. Cancer 2008;112(5):962-5
   PubMed Web of Science ®Google Scholar
• Dezube BJ, Krown SE, Lee JY, et al. Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 2006;24(9):1389-94
   PubMed Web of Science ®Google Scholar
• Krown SE, Roy D, Lee JY, et al. Rapamycin with antiretroviral therapy in AIDS-associated Kaposi sarcoma: an AIDS Malignancy Consortium study. J Acquir Immune Defic Syndr 2012;59(5):447-54
   PubMed Web of Science ®Google Scholar
• Lechowicz M, Dittmer DP, Lee JY, et al. Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic acid. Clin Infect Dis 2009;49(12):1946-9
   PubMed Web of Science ®Google Scholar
• Krown SE, Dittmer DP, Cesarman E. Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma. J Infect Dis 2011;203(8):1082-6
   PubMed Web of Science ®Google Scholar
• Chatterjee D, Chandran B, Berger EA. Selective killing of Kaposi's sarcoma-associated herpesviruslytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein. MAbs 2012;4:2
   PubMed Web of Science ®Google Scholar
• Ye F, Lattif AA, Xie J, et al. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells. Cell Cycle 2012;11(7):1393-9
   PubMed Web of Science ®Google Scholar
• Roy D, Sin SH, Lucas A, et al. mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis. Cancer Res 2013;73(7):2235-46
   PubMed Web of Science ®Google Scholar
• Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):1317-23
   PubMed Web of Science ®Google Scholar
• Yaich S, Charfeddine K, Zaghdane S, et al. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases. Transplant Proc 2012;44(9):2824-6
   PubMed Web of Science ®Google Scholar
• Koon H, Pantanowitz L, Dezube BJ. Antiangiogenic therapy for Kaposi's sarcoma. In: Davis DW, Herbst RS, Abbruzzese JL, editors. Antiangiogenic cancer therapy. CRC Press; Boca Raton: 2007. p. 755-83
   Google Scholar
• Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy. J Clin Oncol 2012;30(13):1476-83
   PubMed Web of Science ®Google Scholar
• Monini P, Sgadari C, Grosso MG, et al. Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 2009;23(4):534-8
   PubMed Web of Science ®Google Scholar
• Reid EG. Bortezomib-induced Epstein-Barr virus and Kaposi sarcoma herpesvirus lytic gene expression: oncolytic strategies. Curr Opin Oncol 2011;23(5):482-7
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Pantanowitz L. New drug targets in Kaposi sarcoma. Expert Opin Ther Targets 2010;14(12):1-12
   PubMedGoogle Scholar